Boston Scientific Corporation（BSX）のニュースとイベントBSXBoston Scientific Corporation

Company Cuts FY26 Revenue Outlook to 4.25% Growth

Consensus $3.23. Cuts FY26 revenue view to up 4.25% from up 5.5%-6.5%. The company said, "The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges, of $3.16 to $3.18."

Company Expects Q4 2026 Revenue Down 1%-3%

Sees Q4 revenue down 1%-3%. The company said, "The company estimates net sales to decline in the fourth quarter of 2026, versus the prior year period, by approximately (3.0) to (1.0) percent on a reported and organic basis. Fourth quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges, of $0.77 to $0.79."

Boston Scientific Appoints Joseph Fitzgerald as COO

Boston Scientific announced the appointment of Joseph Fitzgerald to executive vice president and COO, effective Jan. 1, 2027. In this role, Fitzgerald will oversee the company's global operations, business units and regions. In connection with Fitzgerald's appointment, Boston Scientific will establish three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg also effective Jan. 1.